Okabena Investment Services Inc. Invests $821,000 in Globus Medical, Inc. $GMED

Okabena Investment Services Inc. acquired a new position in shares of Globus Medical, Inc. (NYSE:GMED) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 9,403 shares of the medical device company’s stock, valued at approximately $821,000.

Other institutional investors have also bought and sold shares of the company. Advisory Services Network LLC acquired a new stake in Globus Medical in the 3rd quarter valued at $26,000. EverSource Wealth Advisors LLC boosted its stake in Globus Medical by 74.3% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock valued at $27,000 after buying an additional 197 shares in the last quarter. SBI Securities Co. Ltd. boosted its stake in Globus Medical by 98.2% in the 4th quarter. SBI Securities Co. Ltd. now owns 337 shares of the medical device company’s stock valued at $29,000 after buying an additional 167 shares in the last quarter. Parallel Advisors LLC boosted its stake in Globus Medical by 45.1% in the 3rd quarter. Parallel Advisors LLC now owns 557 shares of the medical device company’s stock valued at $32,000 after buying an additional 173 shares in the last quarter. Finally, Headlands Technologies LLC boosted its stake in Globus Medical by 485.4% in the 2nd quarter. Headlands Technologies LLC now owns 761 shares of the medical device company’s stock valued at $45,000 after buying an additional 631 shares in the last quarter. Institutional investors and hedge funds own 95.16% of the company’s stock.

Insider Buying and Selling

In related news, Director David D. Davidar sold 25,000 shares of the company’s stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $80.76, for a total value of $2,019,000.00. Following the completion of the sale, the director owned 510,175 shares in the company, valued at approximately $41,201,733. This represents a 4.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Corporate insiders own 18.38% of the company’s stock.

Globus Medical Trading Down 3.9%

NYSE GMED opened at $77.25 on Tuesday. The stock has a 50-day simple moving average of $85.56 and a 200 day simple moving average of $88.00. The company has a market capitalization of $10.49 billion, a PE ratio of 17.97, a P/E/G ratio of 1.66 and a beta of 0.95. Globus Medical, Inc. has a 12 month low of $51.79 and a 12 month high of $101.40.

Globus Medical (NYSE:GMED) last released its quarterly earnings data on Thursday, May 7th. The medical device company reported $1.12 EPS for the quarter, beating analysts’ consensus estimates of $0.92 by $0.20. The business had revenue of $759.85 million during the quarter, compared to the consensus estimate of $740.35 million. Globus Medical had a return on equity of 13.46% and a net margin of 18.92%.The firm’s revenue was up 27.0% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.68 earnings per share. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. As a group, sell-side analysts predict that Globus Medical, Inc. will post 4.74 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

GMED has been the topic of several recent analyst reports. Wall Street Zen lowered Globus Medical from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Needham & Company LLC boosted their price target on Globus Medical from $114.00 to $117.00 and gave the company a “buy” rating in a research note on Friday, May 8th. Wells Fargo & Company decreased their price target on Globus Medical from $104.00 to $103.00 and set an “overweight” rating on the stock in a research note on Friday, May 8th. Zacks Research upgraded Globus Medical from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, March 3rd. Finally, Truist Financial set a $115.00 price objective on Globus Medical in a research report on Wednesday, February 25th. Two investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Globus Medical has a consensus rating of “Moderate Buy” and a consensus price target of $105.00.

About Globus Medical

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.